Getinge AB Reports Stable Growth Amid Challenges

Getinge AB ( (GNGBY) ) has released its Q2 earnings. Here is a breakdown of the information Getinge AB presented to its investors.

Getinge AB is a global medical technology company specializing in life support solutions, infection control, and surgical workflows, with a strong presence in acute care therapies and life sciences. In its latest earnings report for Q2 2025, Getinge AB reported stable organic growth in order intake and sales, despite facing challenges from tariffs and currency fluctuations. The company achieved a 4.1% organic increase in net sales and a 4.4% rise in order intake. Key highlights include a strong performance in Acute Care Therapies, particularly in ventilators and cardiac surgery, and significant growth in the Surgical Workflows segment, driven by infection control and digital health solutions. Getinge’s adjusted EBITA rose slightly, despite the impact of tariffs and currency effects, and the company continued to focus on price adjustments and cost management to mitigate these challenges. Looking ahead, Getinge’s management remains optimistic about the company’s prospects for the remainder of 2025, with expectations of continued organic sales growth across all business areas and regions, despite elevated geopolitical risks.